Skin pathogens (plural collective term for pathogenic skin microbes; no single canonical molecular entity)

Skin pathogens encompass a diverse group of microorganisms, predominantly Gram-positive bacteria such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, and Corynebacterium species, that opportunistically infect the skin following barrier disruption from trauma, burns, or underlying conditions like diabetes. These pathogens cause a spectrum of skin and soft tissue infections (SSTIs), ranging from superficial issues like impetigo and folliculitis to severe conditions including cellulitis, abscesses, and necrotizing fasciitis, often entering through breaks in the epidermal barrier and producing virulence factors like toxins or enzymes that exacerbate tissue damage and inflammation. While commensal skin microbiota (e.g., coagulase-negative staphylococci) typically defend against pathogens, dysbiosis or host immunosuppression shifts the balance toward infection. Therapeutically, skin pathogens are managed with antibiotics selected empirically based on likely etiology (e.g., anti-MRSA agents for purulent infections), surgical drainage for abscesses, and emerging topical antimicrobials like peptides to minimize systemic resistance risks. No single molecular target exists due to their microbial nature, posing challenges like rising multidrug resistance (e.g., MRSA, VRSA) that complicates treatment and drives need for novel narrow-spectrum agents or microbiome-modulating strategies.

Other names

Skin flora pathogenscutaneous pathogensSSTI pathogensbacterial skin infection agents

Bacterial cell wall synthesis inhibition (beta-lactams, vancomycin), protein synthesis inhibition (clindamycin, linezolid), cell membrane disruption (daptomycin, antimicrobial peptides), nucleic acid synthesis inhibition (trimethoprim-sulfamethoxazole)